PT-141 Palatin

Current Opinion in Investigational Drugs

Volumn 5, Issue 4, 2004, Pages 456-462

  Hedlund, Petter ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; CYCLOPEPTIDE; MELANOCORTIN RECEPTOR; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; PT-141;

ANIMAL; CHEMISTRY; DRUG POTENTIATION; HUMAN; IMPOTENCE; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ALPHA-MSH; ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; IMPOTENCE; MALE; PEPTIDES, CYCLIC; RECEPTORS, MELANOCORTIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3042583626     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo controlled crossover study. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N J UROL 1998 160 2 389-393
2. Palatin Technologies will begin clinical development of PT-141 erectile dysfunction drug. Palatin Technologies Inc PRESS RELEASE 2000 June 22
3. Palatin Technologies initiates phase I safety study of PT-141 erectile dysfunction drug. Palatin Technologies Inc PRESS RELEASE 2001 February 01
4. Palatin Technologies reports PT-141 phase I clinical results. Palatin Technologies Inc PRESS RELEASE 2001 May 31
5. Effects of PT-141 on erectile dysfunction in adult male Sprague-Dawley rats and rhesus macaques. Herbert GW, Shadiack AM, Koegler FH, Cameron JL J UROL 2001 165 5 Suppl 229 Abs 943
6. Palatin Technologies reports positive PT-141 clinical results; phase II study in men with erectile dysfunction is ongoing. Palatin Technologies Inc PRESS RELEASE 2002 February 19
7. Drug development pipeline: PT-141. Palatin Technologies Inc COMPANY COMMUNICATION 2002 February 21
8. Competitive Technologies' licensee initiates study of sexual dysfunction drug - Palatin Technologies conducting phase I safety study of PT-141 erectile dysfunction drug. Competitive Technologies Inc PRESS RELEASE 2002 February 20
9. American Urological Association - 97th Annual Meeting (Part I), Orlando, FL, USA. Susman E IDDB MEETING REPORT 2002 May 25-30
10. Complete phase IIA data presented for PT-141: Palatin's treatment for male erectile dysfunction. Palatin Technologies Inc PRESS RELEASE 2002 September 24
11. Palatin Technologies reports phase I data for PT-141: Palatin's treatment for sexual dysfunction. Palatin Technologies Inc PRESS RELEASE 2002 September 26
12. Palatin Technologies' PT-141 selectively increases female sexual behavior in preclinical studies. Palatin Technologies Inc PRESS RELEASE 2002 October 14
13. Effects of PT-141, a selective melanocortin receptor agonist, on sexual behavior in female rats. Pfaus JG, vanSoest T, Shadiack A, Molinoff P ABSTR SOC NEUROSCI 2002 28 Abs 482.4
14. Palatin Technologies reports positive PT-141 data in patients with an inadequate response to Viagra. Palatin Technologies Inc PRESS RELEASE 2003 January 22
15. Positive phase IIA data for Palatin's PT-141 presented at the American Urological Association Meeting. Palatin Technologies Inc PRESS RELEASE 2003 April 28
16. Palatin begins enrollment in PT-141 phase IIb at-home clinical study. Palatin Technologies Inc PRESS RELEASE 2003 May 13
17. Palatin Technologies Inc issued US patent for PT-141 novel treatment for male and female sexual dysfunction. Palatin Technologies Inc PRESS RELEASE 2003 June 24
18. Palatin Technologies Inc completes enrollment for phase IIB at-home trial of PT-141. Palatin Technologies Inc PRESS RELEASE 2003 July 24
19. PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY ANN NY ACAD SCI 2003 994 96-102
20. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Pfaus G, Van Soest T, Shadiack A HORM BEHAV 2002 41 4 Abs 484
21. 505320 HPLC-MS/MS assay method for the determination of PT-141 in human and rat plasma. Sheldon C, Maddox H, Orr S, McCush F, Velagaleti PR, Shadiack DA, De M DRUG METAB REV 2001 33 53
22. Activation of melanocortin MC4 receptors increases erectile activity in rats ex copula. Martin WJ, McGowan E, Cashen DE, Gantert LT, Drisko JE, Hom GJ, Nargund R, Sebhat I, Howard AD, Van der Ploeg LH, MacIntyre DE EUR J PHARMACOL 2002 454 1 71-79
23. Palatin Technologies meets primary and secondary endpoints in PT-141 phase IIb study on erectile dysfunction. Palatin Technologies Inc PRESS RELEASE 2003 November 01
24. Elucidating the mechanism of the erectogenic effects of PT-141, a synthetic melanocortin agonist. Shadiack AM, Herbert GW, Silvester KR, Padron JM ABSTR SOC NEUROSCI 2003 33 Abs 399.4
25. Central neural regulation of penile erection. Giuliano F, Rampin O NEUROSCI BIOBEHAV REV 2000 24 5 517-533
26. Pharmacology of penile erection. Andersson KE PHARMACOL REV 2001 53 3 417-450
27. The role of melanocortins in body weight regulation: Opportunities for the treatment of obesity. MacNeil DJ, Howard AD, Guan X, Fong TM, Nargund RP, Bednarek MA, Goulet MT, Weinberg DH, Strack AM, Marsh DJ, Chen HY et al EUR J PHARMACOL 2002 450 1 93-109
28. The melanocortin system. Gantz I, Fong TM AM J PHYSIOL -ENDOCRINOL METAB 2003 284 E468-E474
29. ACTH- and α-MSH-induced grooming, stretching, yawning and penile erection in male rats: Site of action in the brain and role of melanocortin receptors. Argiolas A, Melis MR, Murgia S, Schioth HB BRAIN RES BULL 2000 51 5 425-431
30. α-Melanocyte stimulating hormone and oxytocin induced penile erections, and intracavernous pressure increases in the rat. Mizusawa H, Hedlund P, Andersson KE J UROL 2002 167 2 Pt 1 757-760
31. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME LIFE SCI 1996 58 20 1777-1784
32. Effect of an α-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N UROLOGY 2000 56 4 641-646
33. Identification of a receptor for γ melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, Entwistle ML, Simerly RB, Cone RD PROC NATL ACAD SCI USA 1993 90 19 8856-8860
34. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: Evidence of a cellular basis for the adipostat. Cowley MA, Pronchuk N, Fan W, Dinulescu DM, Colmers WF, Cone RD NEURON 1999 24 1 155-163
35. Interaction of oestradiol, α-melanotrophin and noradrenaline within the ventromedial nucleus in the control of female sexual behaviour. Gonzalez MI, Celis ME, Hole DR, Wilson CA NEUROENDOCRINOLOGY 1993 58 2 218-226
36. The role of melanocortin receptors in sexual behavior in female rats. Cragnolini A, Scimonelli T, Celis ME, Schioth HB NEUROPEPTIDES 2000 34 3-4 211-215
37. 2 induces penile erection via brain and spinal melanocortin receptors. Wessells H, Hruby VJ, Hackett J, Han G, Balse-Srinivasan P, Vanerah TW NEUROSCIENCE 2003 118 3 755-762
38. Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Trivedi P, Jiang M, Tamvakopoulos CC, Shen X, Yu H, Mock S, Fenyk-Melody J, Van der Ploeg LH, Guan XM BRAIN RES 2003 977 2 221-230
39. Melanocortin receptor agonists, penile erection, and sexual motivation: Human studies with Melanotan II. Wessells H, Levine N, Hadley ME, Dorr R, Hruby VJ INT J IMPOT RES 2000 12 Suppl 4 S74-S79
40. An evaluation of the safety and efficacy of intranasally administered PT-141. Diamond LE, Earle DC, Shadiack A, Rosen RC, Molinoff P INT J IMPOT RES 2002 14 Suppl 3 S20 Abs C2.4
41. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB INT J IMPOT RES 2004 16 1 51-59